56 studies found for:    PSMA
Show Display Options
Rank Status Study
1 Recruiting 68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 68Ga-PSMA
2 Recruiting Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients
Condition: Prostate Cancer
Intervention: Drug: Ga-68 labeled HBED-CC PSMA PET imaging
3 Not yet recruiting 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Conditions: Prostate Adenocarcinoma;   PSA Failure;   Recurrent Prostate Carcinoma
Interventions: Procedure: Computed Tomography;   Radiation: Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography
4 Active, not recruiting 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
Condition: Recurrent Prostate Carcinoma
Interventions: Procedure: Computed Tomography;   Radiation: Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx);   Other: Laboratory Biomarker Analysis;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography
5 Completed Efficacy of Portion Size Measurement Aids
Conditions: Nutrition Assessment;   Obesity
Intervention: Behavioral: Portion Size Measurement Aids (PSMAs)
6 Completed A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
7 Completed An Open-label Treatment Extension of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
8 Completed
Has Results
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
Conditions: GBM;   Glioblastoma Multiforme;   Gliosarcoma
Intervention: Drug: PSMA ADC
9 Completed Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
10 Active, not recruiting
Has Results
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Condition: Prostate Cancer
Interventions: Biological: Peptide Vaccine;   Drug: Poly IC-LC
11 Active, not recruiting Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Condition: Monitor Adverse Events
Intervention: Drug: Anti-PSMA Designer T Cells
12 Completed Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
13 Active, not recruiting Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Condition: Prostate Cancer
Intervention: Biological: Gene Modified T Cells
14 Recruiting Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
Condition: Prostate Cancer
Interventions: Biological: engineered autologous T cells;   Drug: cyclophosphamide
15 Completed Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel
Condition: Prostate Cancer
Intervention: Biological: rsPSMA protein plus Alhydrogel® vaccine
16 Recruiting Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Biological: anti-PSMA monoclonal antibody MDX1201-A488;   Procedure: robot-assisted laparoscopic surgery;   Other: diffuse optical imaging;   Other: pharmacological study
17 Active, not recruiting Vaccine Therapy in Treating Patients With Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: human prostate-specific membrane antigen plasmid DNA vaccine;   Biological: mouse prostate-specific membrane antigen plasmid DNA vaccine
18 Not yet recruiting Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
Condition: Clear Cell Renal Cell Carcinoma
Intervention: Drug: G-202
19 Active, not recruiting Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 18F-DCFBC
20 Unknown  Evaluation of a Transrectal Scintigraphic Detector(ProxiScanTM) for Detection of Primary Prostate Cancer
Condition: Suspected Primary Prostate Cancer
Intervention: Device: ProxiScan (scintigraphic rectal probe)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years